Longjin Pharmaceutical(002750)2025-01-21 12:15Financial Performance - The company expects a total profit loss between 33.26 million and 49.50 million CNY for the fiscal year 2024, compared to a loss of 82.24 million CNY in the previous year[3] - The net profit attributable to shareholders is projected to be a loss between 29.82 million and 44.38 million CNY, down from a loss of 70.94 million CNY year-over-year[3] - Operating revenue is estimated to be between 50.87 million and 74.60 million CNY, significantly lower than 86.62 million CNY in the same period last year[3] - The company’s total equity attributable to shareholders is projected to be between 467.51 million and 482.07 million CNY, down from 511.89 million CNY at the end of the previous year[3] Cost Management - The company implemented a 67% price reduction for its injectable product, leading to a decrease in operating revenue due to centralized procurement policies[6] - The company has adopted cost-reduction and efficiency-enhancement measures, resulting in improved production capacity utilization and reduced production costs[6] - R&D expenses have decreased as projects enter the capitalization phase, contributing to a reduction in overall losses compared to the previous year[6] Operational Stability - The company has not planned any major asset restructuring or share issuance recently, maintaining operational stability[7] - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the regular report[4] - The company is under a delisting risk warning due to negative audited net profit and operating revenue below 100 million CNY for the fiscal year 2023[7]